Experience in treating portal thromboses in patients with chronic myeloproliferative diseases

Melikjan A.L.

GBOU VPO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii, Moskva

Sukhanova G.A.

Gematologicheskiĭ nauchnyĭ tsentr, Moskva

Vakhrusheva M.V.

FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva

Subortseva I.N.

FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva

Orel E.B.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Experience in treating portal thromboses in patients with chronic myeloproliferative diseases

Authors:

Melikjan A.L., Sukhanova G.A., Vakhrusheva M.V., Subortseva I.N., Orel E.B.

More about the authors

Journal: Therapeutic Archive. 2016;88(1): 89‑95

DOI: 10.17116/terarkh201688189-95

Downloaded: 106

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Melikjan AL, Sukhanova GA, Vakhrusheva MV, Subortseva IN, Orel EB. Experience in treating portal thromboses in patients with chronic myeloproliferative diseases. Therapeutic Archive. 2016;88(1):89‑95. (In Russ.)
https://doi.org/10.17116/terarkh201688189-95

Close metadata

Recommended articles:

Successful endovascular treatment of proximal deep vein thrombosis following May-Thurner syndrome. Pirogov Russian Journal of Surgery. 2024;(9):99-105

Analysis of risk factors associated with ischemic stroke in the setting of Ph-negative myeloproliferative diseases. Russian Journal of Preventive Medicine. 2025;(1):50-56

Immunohistochemical method of megakaryocytic lineage staining in bone marrow biopsy specimens as an additional pathomorphological differential diagnostic sign of primary myelofibrosis and essential thrombocythemia. Russian Journal of Archive of Pathology. 2025;(1):22-27

Patients with myeloproliferative diseases (MPD) are noted to be at high risk for portal thromboses. This problem gives rise to disability if it is untimely treated or resistant to therapy. The paper gives the experience of the Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation, in using antithrombin III in MPD patients (3 patients with primary myelofibrosis, 3 with essential thrombocythemia) and acute and subacute portal vein thromboses resistant to therapy with direct anticoagulants. In all 5 cases, the use of antithrombin III in combination with low-molecular-weight heparin showed a positive clinical effect as rapid relief of pain syndrome and comparatively early (3-week to 1.5—2-month) recanalization of thrombosed vessels. Three clinical cases are described in detail.

Keywords:

antithrombin III

thrombosis

thrombophilia

chronic myeloproliferative diseases

polycythemia vera

essential thrombocythemia

primary myelofibrosis

JAK2 V617F mutation

treatment of thromboses

Authors:

Melikjan A.L.

GBOU VPO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii, Moskva

Sukhanova G.A.

Gematologicheskiĭ nauchnyĭ tsentr, Moskva

Vakhrusheva M.V.

FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva

Subortseva I.N.

FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva

Orel E.B.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

List of references:

Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22. doi:10.1038/sj.leu.2404955.
Skoda R. The genetic basis of myeloproliferative disorders. ASH Education Book. 2007;2007(1):1-10. doi:10.1182/asheducation-2007.1.1.
Briere JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost. 2006;32(3):208-218. doi:10.1055/s-2006-939432.
Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol. 2000;32:865-871. doi:10.1016/s0168-8278(00)80259-7.
Janssen HL. Changing perspectives in portal vein thrombosis. Scand JGastroenterol. 2000;232:69-73.
Sobhonslidsuk A, Reddy KR. Portal vein thrombosis: A concise review. Am J Gastroenterol. 2002;97:535-541. doi:10.1111/j.1572-0241.2002.05527.x.
Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020-2028. doi:10.1038/leu.2008.253.
Marchioli R, Finazzi G, Landolfi R, Landolfi R, Kutti J., Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232. doi:10.1200/jco.2005.07.062.
Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670. doi:10.1182/blood-2004-09-3426.
Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM. Influence of JAK V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93(1):41-48. doi:10.3324/haematol.11653.
Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006;108(7):2173-2181. doi:http://dx.doi.org/10.1182/blood-2006-02-005751.
Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922-4929. doi:10.1182/blood-2007-11-125328.
Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell’Era A, Bucciarelli P, Mannucci PM. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44(6):1528-1534. doi:10.1002/hep.21435.
Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2):231-219. doi:10.1182/blood-2007-12-128454.
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270. doi:10.1371/journal.pmed.0030270.
Thiele J, Kvasnicka HM. Myelofibrotic transformation in essential thrombocythemia. Haematologica. 2009;94(3):431-433. doi:10.3324/haematol.2008.001446.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumors of haematopoietic and lymphoid tissues. Fourth Edition. Lyon: IARC-press; 2008.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124. doi:10.1056/nejmoa035572.
Kuznik B.I. Fiziologiya i patologiya sistemy krovi. Chita: Poligraf Servis; 2004.
Abildgaard U. Biological action and clinical significance of antithrombin III. Am J Hematol. 1984;16(1):77-79.
Schatz S, Turecek PL, Fiedler C, Zimmermann K, Gritsch H, Voorberg J, Schwarz HP, Dorner F, Scheiflinger F. Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse model. Works-2000. 28 p. Br J Haematol. 2003;123(4):692-895. doi:10.1046/j.1365-2141.2003.04674.x.
Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis. 2006;17(7):521-526. doi:10.1097/01.mbc.0000245302.18010.40.
Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis. 2002;13(8):657-670. doi:10.1097/00001721-200212000-00001.
Patent RF na izobretenie №2477636/ 20.03.2013. Byul. №8. Sukhanova G.A., Stotskaya T.V, Parovichnikova E.N., Vakhrusheva M.V., Vasil'eva E.V., Rudakova V.E. Sposob lecheniya ostrykh venoznykh trombozov razlichnoi lokalizatsii na fone gemorragicheskikh oslozhnenii. Dostupno po: http://www.freepatent.ru/images/patents/433/2477636/patent-2477636.pdf. Ssylka aktivna na 29.10.2015.

Close metadata